Delhi has less than a day's stock of coronavirus vaccines left, with nearly 30,000 doses administered on July 19, according to a bulletin issued on Tuesday. The national capital, as on Tuesday morning, had a balance stock of 2,63,170 coronavirus vaccines, out of which 1,95,290 doses are of Covishield and 67,880 of Covaxin, data shared by the government showed. However, only 20 per cent of the Covaxin stock is to be used, since its stock is limited and has irregular delivery cycles, it noted. Only 25,986 doses were administered on Monday, of which 16,704 were first doses and 9,282 second doses. As many as 93,83,468 vaccine doses have been administered in the national capital till date, including 22,25,292 are second doses. Delhi's current vaccination capacity stands at 47,605 doses per day.
In a written reply to a question in the Rajya Sabha, MoS for Health Bharati Pravin Pawar said as on July 16, a total of 2.61 lakh doses of the Sputnik V vaccine have been administered in the country
The British government decided on Monday not to inoculate most children and teenagers against COVID-19 until more data on the available vaccines becomes available.
No one disputes that the world is unfair. But no one expected a vaccine gap between the global rich and poor that was this bad, this far into the pandemic
America's Surgeon General Dr Vivek Murthy on Sunday expressed concern over the 'significant increase' in Covid-19 cases in the US, especially among the unvaccinated population
Delhi had less than a day's stock of coronavirus vaccine doses left on Sunday morning, according to the vaccination bulletin issued by the city government
More than 46.38 lakh (46,38,106) vaccine doses were administered on Saturday, the report said
Retail boom will be directly correlated to vaccination levels, Shoppers Stop MD and CEO Venu Nair said
Pandemic has posed unprecedented challenges disrupting global supply chains and slowing down economic activity
Some business owners are uncomfortable with having to enforce the rules
Centre has placed an order to procure 660 million more doses of Covishield and Covaxin at a revised price of Rs 205 and Rs 215 per dose, respectively, excluding taxes.
Hungarian government will offer citizens the option of receiving a third dose of the Covid-19 vaccine starting in August, Prime Minister Viktor Orban said
White House Covid Response team is warning Americans that US outbreak is becoming 'a pandemic of unvaccinated' and nearly all hospital admissions and deaths are now among those who have not got shots
At key APEC meeting, they vow to accelerate access to Covid-19 vaccines
Many inoculation centres in Uttar Pradesh have shut down due to shortage of vaccine doses and people are wandering in search of vaccines, Samajwadi Party (SP) president Akhilesh Yadav said on Friday.
The stock of anti-coronavirus vaccines in the national capital will last for a day only, claimed an official bulletin issued on Friday. The city had administered 33,186 vaccine doses on Thursday of which 21,189 were first jabs and 11,997 second. According to official data, the total number of vaccine doses administered in Delhi so far has reached 91,86,905. On Friday morning, Delhi had 2,27,600 doses of Covaxin and 1,13,900 doses of Covishield in its balance stock. This was after 1,04,150 doses of Covishield were added to the stock on Thursday. According to the Delhi government, since Covaxin stock is "limited and have irregular delivery cycle" only 20 per cent of it can be used for first dose. The vaccination programme is running at 1,374 centres with a capacity of administering 2,26,552 vaccine doses daily.
Prime Minister Narendra Modi on Friday urged states where Covid-19 cases are rising to take proactive measures to prevent a third wave
Los Angeles County's health department said it has reimposed an indoor mask mandate regardless of individuals' vaccination status
While many big hospital chains are sustaining vaccination on the leftover stock from previous orders, smaller hospitals are unable to access vaccines through any channel
A host of lesser-known vaccine makers are eyeing contract manufacturing opportunities for global and domestic majors